Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1070 of 6351
-
New chemo cocktail shows promise against tough pancreatic cancer
Disease control CompletedA randomized phase II study to compare the efficacy and safety of SLOG or mFOLFIRINOX as a first-line treatment for patients with locally advanced and metastatic pancreatic cancer.
Phase 2 • Sponsor: National Health Research Institutes, Taiwan • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Heart attack prevention showdown: proactive care vs. standard care
Prevention OngoingThe primary objective of this study is to test the effectiveness of a proactive cardiovascular primary prevention strategy, with or without the use of coronary calcium screening, compared to current standard care, in preventing future major adverse cardiac events (MACE), includin…
Sponsor: Intermountain Health Care, Inc. • Aim: Prevention
Last updated Jun 27, 2026 12:08 UTC
-
New targeted pill shows promise for tough bladder cancers
Disease control OngoingThe purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor receptor (FGFR) aberrations who have progressed after 1 or 2 prior treatments, at leas…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Canadian trial matches cancer drugs to gene mutations
Disease control Recruiting nowCancer drugs which target the effects of abnormal gene changes are called 'targeted therapies'. This study, called PM.1 or CAPTUR, will include some targeted therapies that are currently available. The purpose of this study is to find out what are the effects on a patient and the…
Phase 2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New drug combo aims to boost stem cell harvest in myeloma patients
Disease control OngoingA total of 122 subjects were randomized into the study and investigated in the double-blind placebo-controlled setting to assess the efficacy and safety of G-CSF + BL-8040 as compared to G-CSF + placebo.
Phase 3 • Sponsor: BioLineRx, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New pill shows promise for rare bleeding disorder
Disease control CompletedThis was a 2 part (Part A and B) adaptive, open-label, dose-finding study of PRN1008 in patients with ITP who are refractory or relapsed with no available and approved therapeutic options, with a platelet count \<30,000/μL on two counts no sooner than 7 days apart in the 15 days …
Phase 2 • Sponsor: Principia Biopharma, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Can a new gemcitabine formulation outsmart advanced solid tumors?
Disease control OngoingTo determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT) and recommended Phase 2 dose (RP2D) in patients who receive FF-10832 (Gemcitabine Liposome Injection) for treatment of advanced solid tumors including biliary tract cancer
Phase 1 • Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can surgery boost survival in metastatic prostate cancer?
Disease control OngoingThis is a phase 2.5 international, multi-institution, randomized clinical trial to evaluate the potential therapeutic effect of CRP combined with the BST in men with mPCa prospectively. Such hybrid design permits the inclusion of the patients who have accrued to the phase 2 inves…
Phase 2 • Sponsor: Yale University • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New drug cocktail targets tough blood cancers
Disease control Recruiting nowThis phase Ib/II trial studies the side effects and best dose of venetoclax and how well it works when given together with ivosidenib with or without azacitidine, in treating patients with IDH1-mutated hematologic malignancies. Venetoclax and ivosidenib may stop the growth of can…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New hope for bladder cancer patients who Can't take chemo?
Disease control OngoingA Phase II, Randomized, Multi-Center, Double-Blind, Comparative Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Olaparib for First-Line Treatment in Platinum-Ineligible Patients With Unresectable Stage IV Urothelial Cancer
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Could some rectal cancer patients skip surgery? new study investigates
Disease control Recruiting nowThis is a 5 year Phase II study to evaluate the safety of non-operative management (NOM) in patients with low rectal cancer (LRC) who achieve a complete clinical response (cCR) following chemoradiotherapy (CRT). The safety of NOM will be evaluated by assessing (i) rate of local r…
Sponsor: Mount Sinai Hospital, Canada • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New combo vaccine and immunotherapy tackles Hard-to-Treat breast cancer
Disease control CompletedThis is an open-label, phase I/II double arm study of the SV-BR-1-GM regimen in combination with retifanlimab in patients with metastatic or locally recurrent breast cancer who have failed standard therapy. Patients will receive the SV-BR-1-GM regimen with combination immunother…
Phase 1/2 • Sponsor: BriaCell Therapeutics Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Massive trial tests cheap drug to stop Post-C-Section hemorrhage
Prevention CompletedA randomized placebo-controlled trial of 11,000 women to assess whether tranexamic acid as prophylaxis lowers the risk of postpartum hemorrhage in women undergoing a cesarean delivery.
Phase 3 • Sponsor: The George Washington University Biostatistics Center • Aim: Prevention
Last updated Jun 27, 2026 14:02 UTC
-
Immunotherapy may replace chemo in head and neck cancer trial
Disease control OngoingThe purpose of this study is to compare any good or bad effects of using pembrolizumab (an experimental drug) and radiation therapy (RT), compared to using cisplatin chemotherapy and radiation therapy (RT) in the treatment of patients with head and neck squamous cell carcinoma (H…
Phase 2 • Sponsor: Loren Mell, MD • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New hope for young migraine sufferers: drug shows promise in landmark trial
Disease control OngoingThe main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of…
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:15 UTC
-
New immune combo shows promise against stubborn lymphoma
Disease control CompletedThis is a Phase 2 non-randomized, open label, uncontrolled, efficacy and safety study. Study participants will receive two priming doses of 0.5mL of DPX-Survivac 21 days apart and up to six 0.1ml maintenance injections every two months with low dose metronomic oral cyclophosphami…
Phase 2 • Sponsor: Sunnybrook Health Sciences Centre • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Gene therapy shows promise for rare eye disease that causes blindness
Disease control CompletedThe goal of this clinical trial is to assess the efficacy and safety of GS010 gene therapy - (lenadogene nolparvovec) in subjects with LHON due to the G11778A ND4 mitochondrial mutation with a vision loss up to one year.
Phase 3 • Sponsor: GenSight Biologics • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Shorter radiation after mastectomy may cut side effects
Disease control OngoingThis randomized phase III trial studies how well hypofractionated radiation therapy works in preventing recurrence in patients with stage IIa-IIIa cancer who have undergone mastectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter pe…
Phase 3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New catheter method aims chemo directly at pancreatic tumors
Disease control Recruiting nowThe study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
Phase 3 • Sponsor: RenovoRx • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New drug combo shows promise for tough liver cancer
Disease control CompletedThe purpose of this study is to observe and preliminary explore the efficacy and safety of combination of Apatinib and SHR-1210 regimen in treating advanced hepatocellular carcinoma.
Phase 2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC